This video examines a phase II study that compared atezolizumab with or without bevacizumab vs sunitinib in untreated patients with metastatic renal cell carcinoma.
David F. McDermott, MD
Advertisement
Articles by David F. McDermott, MD
Advertisement
Latest Updated Articles
Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1–Positive mRCCPublished: March 3rd 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma
3
64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC
4
Real-World Data From IMS: Promising Results in Relapsed/Refractory Multiple Myeloma
5
